# US 2023/0058779 A1 · Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058779 A1
- Document ID: US20230058779A1
- Status: Published application
- Kind: A1
- Application number: 17/790,543
- Filed: 2020-12-18
- Published: 2023-02-23
- Earliest claimed: 2020-01-02
- Assignees: Merck Sharp & Dohme Corp.; Eisai R&D Management Co., Ltd.
- Applicants: Merck Sharp & Dohme LLC; EISAI R&D Management Co., LTD.
- Inventors: Rachel A. Altura; Philip E. Brandish; Rodolfo Fleury Perini
- Web page: https://patentgrep.com/patent/US20230058779A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/47: Quinolines; Isoquinolines
- A61K 39/39591: {Stabilisation, fragmentation}
- A61P 13/12: of the kidneys
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are methods of treating cancer (e.g., RCC), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) an ILT4 antagonist; and (c) lenvatinib represented by Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.

## Claims

### Claim 1

A method of treating cancer, comprising administering to a human patient in need thereof:
(a) a PD-1 antagonist;
(b) an ILT4 antagonist; and
(c) lenvatinib represented by Formula (I),
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, non-small cell lung cancer, colorectal cancer, renal cell carcinoma (RCC), hepatocellular carcinoma, and melanoma.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cancer is advanced RCC or metastatic RCC.

### Claim at position 4

4-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the PD-1 antagonist is an anti-human PD-1 monoclonal antibody or antigen binding fragment thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein the PD-1 antagonist is an anti-human PD-L1 monoclonal antibody or antigen binding fragment thereof, wherein the anti-human PD-L1 monoclonal antibody is not atezolizumab.

### Claim 15 (depends on 13)

The method of claim 13, wherein the anti-human PD-1 monoclonal antibody is a humanized antibody or a human antibody.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the ILT4 antagonist is an anti-human ILT4 monoclonal antibody or antigen binding fragment thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the anti-human ILT4 monoclonal antibody is a humanized antibody or a human antibody.

### Claim 19

(canceled)

### Claim 20 (depends on 13)

The method of claim 13, wherein the anti-human PD-1 monoclonal antibody is pembrolizumab.

### Claim 21 (depends on 13)

The method of claim 13, wherein the anti-human PD-1 monoclonal antibody is nivolumab or cemiplimab.

### Claim 22

(canceled)

### Claim 23 (depends on 17)

The method of claim 17, wherein the anti-human ILT4 monoclonal antibody comprises a VL CDR1, a VL CDR2, and a VL CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:1, 2, and 3, respectively, and a VH CDR1, a VH CDR2, and a VH CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:6, 7, and 8, respectively.

### Claim 24 (depends on 17)

The method of claim 17, wherein the anti-human ILT4 monoclonal antibody comprises a VL region comprising an amino acid sequence as set forth in SEQ ID NO:4, and a VH region comprising an amino acid sequence as set forth in SEQ ID NO:9.

### Claim 25 (depends on 17)

The method of claim 17, wherein the anti-human ILT4 monoclonal antibody comprises a light chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:5 and a heavy chain comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:10.

### Claim 26 (depends on 1)

The method of any one of claim 1, wherein:
(a) the PD-1 antagonist is pembrolizumab; and
(b) the ILT4 antagonist is a monoclonal antibody or antigen binding fragment thereof comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:1, 2, and 3, respectively, and a VH CDR1, a VH CDR2, and a VH CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:6, 7, and 8, respectively.

### Claim 27 (depends on 1)

The of claims of claim 1, wherein:
(a) the PD-1 antagonist is nivolumab or cemiplimab; and
(b) the ILT4 antagonist is a monoclonal antibody or antigen binding fragment thereof comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:1, 2, and 3, respectively, and a VH CDR1, a VH CDR2, and a VH CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:6, 7, and 8, respectively.

### Claim 28

(canceled)

### Claim 29 (depends on 26)

The method of claim 26, wherein the human patient is administered 200 mg, 240 mg, or 2 mg/kg pembrolizumab, and wherein pembrolizumab is administered once every three weeks.

### Claim 30 (depends on 26)

The method of claim 26, wherein the human patient is administered 400 mg pembrolizumab, and wherein pembrolizumab is administered once every six weeks.

### Claim 31 (depends on 27)

The method of claim 27, wherein the human patient is administered 240 mg or 3 mg/kg nivolumab once every two weeks, 480 mg nivolumab once every four weeks, or 350 mg cemiplimab once every three weeks.

### Claim 32

(canceled)

### Claim 33 (depends on 29)

The method claim 29, wherein the human patient is administered from about 100 mg to about 1600 mg of the anti-human ILT4 antibody, and wherein the anti-human ILT4 antibody is administered once every three weeks.

### Claim 34

(canceled)

### Claim 35 (depends on 34)

The method of claim 34, wherein the human patient is administered 800 mg of the anti-human ILT4 antibody.

### Claim 36 (depends on 29)

The method of claim 29, wherein the human patient is administered 8, 10, 12, 14, 18, 20, or 24 mg lenvatinib, and wherein lenvatinib is administered once daily.

### Claim 37

A method of treating RCC, comprising administering to a human patient in need thereof:
(a) 200 mg pembrolizumab;
(b) 800 mg of an anti-human ILT4 monoclonal antibody or antigen binding fragment thereof that comprises a VL CDR1, a VL CDR2, and a VL CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:1, 2, and 3, respectively, and a VH CDR1, a VH CDR2, and a VH CDR3 comprising amino acid sequences as set forth in SEQ ID NOS:6, 7, and 8, respectively; and
(c) 20 mg lenvatinib.

### Claim 38 (depends on 37)

The method of claim 37, wherein each of (a) and (b) is administered once every three weeks and wherein (c) is administered once daily.

### Claim 39

(canceled)

### Claim 40 (depends on 39)

The method of claim 39, wherein (a) and (b) are administered on the same day, and wherein (a) and (b) are administered sequentially or concurrently.

### Claim 41 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable salt thereof is lenvatinib mesylate.
